Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AADI NYSE:CANO NASDAQ:CELU NASDAQ:SHLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$1.80-2.7%$1.88$1.21▼$3.81$44.46M0.68258,762 shs76,079 shsCANOCano Health$3.81$1.74▼$190.00$12.39M0.05423,785 shs159,142 shsCELUCelularity$3.03+37.7%$2.06$1.00▼$5.22$52.69M0.74375,569 shs746,361 shsSHLTSHL Telemedicine$2.05$2.05$1.85▼$4.83$33.61M0.1111,689 shsN/A7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience-5.13%-6.09%-7.96%+17.83%+17.83%CANOCano Health0.00%0.00%0.00%0.00%0.00%CELUCelularity+37.73%+43.60%+69.27%+94.86%-5.02%SHLTSHL Telemedicine0.00%0.00%0.00%0.00%-56.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAADIAadi Bioscience0.4706 of 5 stars1.00.00.00.00.02.51.3CANOCano HealthN/AN/AN/AN/AN/AN/AN/AN/ACELUCelularity0.0275 of 5 stars0.00.00.00.00.61.70.0SHLTSHL TelemedicineN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAADIAadi Bioscience 2.00Hold$1.67-7.41% DownsideCANOCano Health 0.00N/AN/AN/ACELUCelularity 0.00N/AN/AN/ASHLTSHL Telemedicine 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$25.07M1.77N/AN/A$4.29 per share0.42CANOCano Health$2.74B0.00N/A0.03$100.28 per share0.00CELUCelularity$54.22M1.34N/AN/A$0.37 per share8.19SHLTSHL Telemedicine$55.94M0.60$0.04 per share54.03$5.21 per share0.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%8/5/2025 (Estimated)CANOCano Health-$207.27M-$215.87N/AN/AN/A-18.62%-133.59%-19.18%N/ACELUCelularity-$57.89M-$2.65N/A∞N/A-106.77%-271.88%-42.82%7/21/2025 (Estimated)SHLTSHL Telemedicine-$7.06MN/A0.00∞N/AN/AN/AN/A9/24/2025 (Estimated)Latest CANO, SHLT, CELU, and AADI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q4 2024CELUCelularity-$1.50-$0.59+$0.91-$0.59$5.20 million$18.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/ACANOCano HealthN/AN/AN/AN/AN/ACELUCelularityN/AN/AN/AN/AN/ASHLTSHL TelemedicineN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.894.54CANOCano Health3.950.400.40CELUCelularity4.070.380.28SHLTSHL Telemedicine0.192.171.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%CANOCano Health35.99%CELUCelularity19.02%SHLTSHL Telemedicine20.11%Insider OwnershipCompanyInsider OwnershipAADIAadi Bioscience37.30%CANOCano Health13.93%CELUCelularity22.10%SHLTSHL TelemedicineN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience4024.70 million15.49 millionOptionableCANOCano Health4,3655.41 million4.65 millionOptionableCELUCelularity22023.95 million18.66 millionOptionableSHLTSHL Telemedicine58316.39 millionN/ANot OptionableCANO, SHLT, CELU, and AADI HeadlinesRecent News About These CompaniesSHL Telemedicine ADR Stock Price HistoryJune 20, 2025 | investing.comSHL Telemedicine Clarifies Voting Process for May 2025 AGMMay 20, 2025 | tipranks.comSHL Telemedicine to Delist ADRs from Nasdaq to Cut CostsMarch 11, 2025 | tipranks.comSHLT SHL Telemedicine Ltd.March 6, 2025 | seekingalpha.comSHL Telemedicine Ltd (SHLTN)January 23, 2025 | investing.comSHL Telemedicine (NASDAQ:SHLT) Stock Quotes, Forecast and News SummaryDecember 18, 2024 | benzinga.comDocGo and SHL Telemedicine Partner to Revolutionize Patient Access to Cardiovascular CareDecember 18, 2024 | businesswire.comSHL Telemedicine (NASDAQ:SHLT) Stock, Short Interest ReportOctober 9, 2024 | benzinga.comSHL Telemedicine to Appoint David Arnon as CEO of SHL TelemedicineJuly 29, 2024 | 01net.it0SHL Telemedicine Confirms Discussions Regarding a Possible Investment in its Israeli ActivityJune 20, 2024 | businesswire.comSHL Telemedicine Expands Offering in Israel With Groundbreaking At-home Biomarker Blood TestMay 21, 2024 | businesswire.comSHL Telemedicine Ltd ADR - NewMay 17, 2024 | morningstar.comMSHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft LaunchMay 16, 2024 | finance.yahoo.comSHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft LaunchMay 16, 2024 | businesswire.comSHL Telemedicine Ltd.: SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical MilestonesApril 17, 2024 | finanznachrichten.deSHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical MilestonesApril 17, 2024 | finance.yahoo.comSHL Telemedicine Ltd. (SHLT)April 16, 2024 | finance.yahoo.comTelehealth clinical trial cuts hospital cardiac readmissions by 76%April 11, 2024 | msn.comImperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine’s SmartHeart® in Post-ACS Patient CareApril 11, 2024 | finance.yahoo.comImperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine's SmartHeart® in Post-ACS Patient CareApril 11, 2024 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCANO, SHLT, CELU, and AADI Company DescriptionsAadi Bioscience NASDAQ:AADI$1.80 -0.05 (-2.70%) As of 07/18/2025Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.Cano Health NYSE:CANOCano Health, Inc. provides primary care medical services to its members in the United States and Puerto Rico. It owns and operates medical centers enabled by CanoPanorama, a proprietary population health management technology-powered platform that provides the healthcare providers at its medical centers with a 360-degree view of their members with actionable insights to improve care decisions and member engagement. The company also operates pharmacies, as well as provides dental services in its medical centers. Cano Health, Inc. was founded in 2009 and is headquartered in Miami, Florida.Celularity NASDAQ:CELU$3.03 +0.83 (+37.73%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$2.85 -0.18 (-5.94%) As of 07/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.SHL Telemedicine NASDAQ:SHLTSHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. It offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; and Cardio'B, a portable device to transmit a 12-lead ECG. The company also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices, including blood pressure, weighing, oxygen saturation level (TelePulse Oximeter), breath exhalation (TeleBreather), and sugar measuring devices; and TelePress, a remote blood pressure monitoring device for personal use. It offers its telemedicine services and devices to subscribers using electronic and telecommunication technologies. The company serves physicians, hospitals, health insurance funds, and patients. It has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and the Hebrew University of Jerusalem and the Hadassah Medical Center. The company was incorporated in 1986 and is headquartered in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
